

## Measurement Period for Denominators and Numerators for the 2026 Child Core Set Measures

Measure	2026 Measurement Period <sup>a</sup>		
	Denominator <sup>b</sup>	Numerator	Continuous Enrollment Period
AAB-CH: Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis: Ages 3 Months to 17 Years	<p>Intake Period: July 1, 2024 – June 30, 2025</p> <p>Negative medication history review: June 1, 2024 – June 30, 2025 (30 days prior to the episode date)</p> <p>Negative comorbid condition history: July 1, 2023 – June 30, 2025 (365 days prior to and including the episode date [366 days total])</p>	<p>July 1, 2024 – July 3, 2025 (Episode date through three days after episode date)</p>	<p>June 1, 2024 – July 3, 2025 (30 days prior to episode date through three days after episode date [34 total days])</p>
ADD-CH: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication	<p>Index prescription start date (IPSD): March 1, 2024 – February 28, 2025</p> <p>Negative medication history: November 2, 2023 – October 31, 2024 (120 days prior to the PSD)</p>	<p>Initiation Phase: March 31, 2024 – March 30, 2025 (30 days following PSD)</p> <p>Continuation and Maintenance Phase: December 26, 2024 – December 25, 2025 (300 days following PSD)</p>	<p>Initiation Phase: November 2, 2023 – March 30, 2025 (120 days prior to PSD through 30 days after the PSD)</p> <p>Continuation and Maintenance Phase: November 2, 2023 – December 25, 2025 (120 days prior to PSD through 300 days after the PSD)<sup>c</sup></p>
AMR-CH: Asthma Medication Ratio: Ages 5 to 18	January 1, 2024 – December 31, 2025	January 1, 2025 – December 31, 2025	January 1, 2024 – December 31, 2025 <sup>d</sup>
APM-CH: Metabolic Monitoring for Children and Adolescents on Antipsychotics	January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025 <sup>e</sup>
APP-CH: Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics	<p>IPSD: January 1, 2025 – December 1, 2025</p> <p>Negative medication history review: September 3, 2024 – August 3, 2025 (120 days before the PSD)</p>	<p>October 3, 2024 – December 31, 2025 (90 days prior to PSD through 30 days after the PSD)</p>	<p>September 3, 2024 – December 31, 2025 (120 days prior to PSD through 30 days after PSD).</p>

Measure	2026 Measurement Period <sup>a</sup>		
	Denominator <sup>b</sup>	Numerator	Continuous Enrollment Period
CCP-CH: Contraceptive Care – Postpartum Women Ages 15 to 20	Delivery Date: January 1, 2025 – September 30, 2025	3-Day Rates: January 1, 2025 – October 3, 2025 (Delivery date through 3 days after delivery date) <sup>f</sup>  90-Day Rates: January 1, 2025 – December 31, 2025 (Delivery date through 90 days after delivery date) <sup>f</sup>	January 1, 2025 – December 31, 2025 (Delivery date through 90 days after delivery date)
CCW-CH: Contraceptive Care – All Women Ages 15 to 20	January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025 <sup>f</sup>	January 1, 2025 – December 31, 2025 <sup>e</sup>
CDF-CH: Screening for Depression and Follow-Up Plan: Ages 12 to 17	January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025	None
CHL-CH: Chlamydia Screening: Ages 16 to 20	January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025 <sup>e</sup>
CIS-CH: Childhood Immunization Status	2nd birthday: January 1, 2025 – December 31, 2025	January 1, 2023 – December 31, 2025 (Birth through 2nd birthday) <sup>g</sup>	January 1, 2024 – December 31, 2025 (12 months prior to 2nd birthday) <sup>e</sup>
CPC-CH: Consumer Assessment of Healthcare Providers and Systems (CAHPS®) Health Plan Survey 5.1H – Child Version Including Medicaid and Children with Chronic Conditions Supplemental Items	Not applicable (varies by survey question; most questions reference “the last 6 months”)	Not applicable (varies by survey question; most questions reference “the last 6 months”)	July 1, 2025 – December 31, 2025 <sup>h</sup>
DEV-CH: Developmental Screening in the First Three Years of Life	1st, 2nd, or 3rd birthday: January 1, 2025 – December 31, 2025	January 1, 2024 – December 31, 2025 (12 months prior to 1st, 2nd, or 3rd birthday)	January 1, 2024 – December 31, 2025 (12 months prior to 1st, 2nd, or 3rd birthday) <sup>e</sup>
FUA-CH: Follow-Up After Emergency Department Visit for Substance Use: Ages 13 to 17	Emergency Department (ED) visit date: January 1, 2025 – December 1, 2025	7-Day Follow-up: January 1, 2025 – December 8, 2025 (ED visit date through 7 days after visit date)  30-Day Follow-up: January 1, 2025 – December 31, 2025 (ED visit date through 30 days after visit date)	January 1, 2025 – December 31, 2025 (ED visit date through 30 days after visit date)

Measure	2026 Measurement Period <sup>a</sup>		
	Denominator <sup>b</sup>	Numerator	Continuous Enrollment Period
FUH-CH: Follow-Up After Hospitalization for Mental Illness: Ages 6 to 17	Discharge date: January 1, 2025 – December 1, 2025	7-Day Follow-up: January 2, 2025 – December 8, 2025 (7 days after discharge date)  30-Day Follow-up: January 2, 2025 – December 31, 2025 (30 days after discharge date)	January 1, 2025 – December 31, 2025 (30 days after discharge date)
FUM-CH: Follow-Up After Emergency Department Visit for Mental Illness: Ages 6 to 17	ED visit date: January 1, 2025 – December 1, 2025	7-Day Follow-up: January 1, 2025 – December 8, 2025 (ED visit date through 7 days after visit date)  30-Day Follow-up: January 1, 2025 – December 31, 2025 (ED visit date through 30 days after visit date)	January 1, 2025 – December 31, 2025 (ED visit date through 30 days after visit date)
IMA-CH: Immunizations for Adolescents	13th birthday: January 1, 2025 – December 31, 2025	Meningococcal Rate: January 1, 2022 – December 31, 2025 (10th through 13th birthday) (or anaphylaxis due to the meningococcal vaccine before or on the 13th birthday)  Tdap Rate: January 1, 2022 – December 31, 2025 (10th through 13th birthday) (or anaphylaxis or encephalitis due to the Tdap vaccine before or on the 13th birthday)  HPV Rate: January 1, 2021 – December 31, 2025 (9th through 13th birthday) (or anaphylaxis due to the HPV vaccine before or on the 13th birthday)	January 1, 2024 – December 31, 2025 (12 months prior to 13th birthday) <sup>e</sup>
LBW-CH: Live Births Weighing Less than 2,500 Grams	Birth date: January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025	None
LRCD-CH: Low-Risk Cesarean Delivery: Under Age 20	Birth date: January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025	None
LSC-CH: Lead Screening in Children	2nd birthday: January 1, 2025 - December 31, 2025	January 1, 2023 - December 31, 2025 (Birth through 2nd birthday)	January 1, 2024 – December 31, 2024 (12 months prior to 2nd birthday) <sup>e</sup>

Measure	2026 Measurement Period <sup>a</sup>		
	Denominator <sup>b</sup>	Numerator	Continuous Enrollment Period
OEV-CH: Oral Evaluation, Dental Services	January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025 (180 days during measurement year)
OEVP-CH: Oral Evaluation During Pregnancy: Ages 15 to 20	Delivery date: January 1, 2025 – December 31, 2025	April 6, 2024 – December 30, 2025 (270 days prior to the delivery date)	July 5, 2024 – December 31, 2025 (180 days prior to delivery through the delivery date)
PDS-CH: Postpartum Depression Screening and Follow-Up: Under Age 21	Delivery date: September 8, 2024 – September 7, 2025	Depression Screening: September 15, 2024 – November 30, 2025 (7 to 84 days following the delivery date)  Follow-up on Positive Screen: – September 15, 2024 – December 31, 2025 (On or up to 30 days after the date of the first positive screen [31 total days]) or – September 15, 2024 – November 30, 2025 (Documentation of additional depression screening on the same day as a positive screen)	September 8, 2024 - November 6, 2025 (Delivery date through 60 days after the delivery date)
PND-CH: Prenatal Depression Screening and Follow-Up: Under Age 21	Delivery date: January 1, 2025 – December 31, 2025	Depression Screening: – Delivery date January 1, 2025 – December 1, 2025: Screening from the pregnancy start date through the delivery date – Delivery date December 2, 2025 – December 31, 2025: Screening from the pregnancy start date through December 1, 2025  Follow-Up on Positive Screen: On or up to 30 days after the date of the first positive screen [31 total days]	December 4, 2024 – December 31, 2025 (28 days prior to the delivery date through the delivery date)

Measure	2026 Measurement Period <sup>a</sup>		
	Denominator <sup>b</sup>	Numerator	Continuous Enrollment Period
PPC2-CH: Prenatal and Postpartum Care: Under Age 21	Delivery date: October 8, 2024 – October 7, 2025	<p>Timeliness of Prenatal Care: Visit in the first trimester: January 2, 2024 – April 14, 2025 (176 to 280 days prior to delivery)</p> <p>Note: Women who were not continuously enrolled (with no gaps) from at least 219 days before delivery through 60 days after delivery must have a prenatal visit any time during the period that begins 280 days prior to delivery and ends 42 days after their enrollment start date (not including visits on or after the date of delivery).</p> <p>Postpartum Care: October 15, 2024 – December 30, 2025 (7 to 84 days after delivery date)</p>	August 26, 2024 – December 6, 2025 (43 days prior to delivery date through 60 days after delivery date)
PRS-CH: Prenatal Immunization Status: Under Age 21	Delivery date: January 1, 2025–December 31, 2025	<p>Influenza Rate: July 1, 2024 – December 31, 2025 (or anaphylaxis due to the influenza vaccine on or before the delivery date)</p> <p>Tdap Rate: March 6, 2024 - December 31, 2025 (During the pregnancy [including on the delivery date] or anaphylaxis or encephalitis due to the Tdap vaccine on or before the delivery date)</p>	December 4, 2024 – December 31, 2025 (28 days prior to the delivery date through the delivery date)
SFM-CH: Sealant Receipt on Permanent First Molars	10th Birthday: January 1, 2025 – December 31, 2025	January 1, 2021 – December 31, 2025 (48 months prior to the 10th birthday) <sup>j</sup>	January 1, 2024 – December 31, 2025 (12 months prior to 10th birthday) <sup>e</sup>
TFL-CH: Topical Fluoride for Children	January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025 <sup>j</sup>

Measure	2026 Measurement Period <sup>a</sup>		
	Denominator <sup>b</sup>	Numerator	Continuous Enrollment Period
W30-CH: Well-Child Visits in the First 30 Months of Life	Rate 1: Well-Child Visits in the First 15 Months 15th month birthday (90 days after child's first birthday): January 1, 2025 – December 31, 2025  Rate 2: Well-Child Visits for Age 15 Months – 30 Months 30th month birthday (180 days after child's second birthday): January 1, 2025 – December 31, 2025	Rate 1: Well-Child Visits in the First 15 Months: October 1, 2023 – December 31, 2025 (Date of birth through 15-month birthday)  Rate 2: Well-Child Visits for Age 15 Months - 30 Months: October 2, 2023 – December 31, 2025 (Day after the 15-month birthday through 30-month birthday)	Rate 1: Well-Child Visits in the First 15 Months: November 1, 2023 – December 31, 2025 (31 days – age 15 months) <sup>e</sup>  Rate 2: Well-Child Visits for Age 15 Months – 30 Months: October 2, 2023 – December 31, 2025 (15 months plus 1 day – age 30 months) <sup>e</sup>
WCC-CH: Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents	January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025 <sup>e</sup>
WCV-CH: Child and Adolescent Well-Care Visits	January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025 <sup>e</sup>

<sup>a</sup> For some measures, the measurement period for the numerator, denominator, or continuous enrollment period varies depending on a specified date for each beneficiary (such as beneficiary birthdates, prescription or treatment start dates, and discharge dates). For these measures, two ranges are shown. The first date range identifies the full range of possible dates that states will need to use to calculate the measure for all measure-eligible beneficiaries. The text in parentheses describes the measurement period that should be used for each eligible beneficiary.

<sup>b</sup> When reporting each measure to CMS, states should indicate whether they defined the measurement period according to Core Set specifications. For many measures, this date range corresponds to calendar year 2025 (January 1, 2025 – December 31, 2025). Some measures also require states to review utilization or enrollment prior to this period to identify the measure eligible population. For example, the ADD-CH measure instruct states to identify beneficiaries with an ADHD prescription dispensing date in the 12-month window beginning March 1 of the year prior to the measurement year and ending the last calendar day of February of the measurement year (the first date range). However, states will also need to review the beneficiary's medication history from four months before the earliest prescription dispensing date to confirm the negative medication history (the second date range). States that followed 2026 Child Core Set specifications (that is, calculated the denominator using prescriptions from March 2024 to February 2025) should select "Yes, our state adhered to Core Set specifications in defining the measurement period for calculating this measure.". States that used a different date range, should answer "No" to this question and provide the Start Date and End Date they used to identify the Denominator (based on the first date range and not the look-back period). States should note variations from any measurement period (numerator, denominator, continuous enrollment) in the "Variations from Measurement Specifications" section.

<sup>c</sup> No more than one gap in enrollment of 45 days between 31 and 300 days after the IPSD.

<sup>d</sup> No more than one gap in enrollment of up to 45 days during each year of the continuous enrollment period.

<sup>e</sup> No more than one gap in enrollment of up to 45 days during the continuous enrollment period.

<sup>f</sup> Applies to both the Most or Moderately Effective Contraception rate and Long-Acting Reversible Contraceptive (LARC) rate.

<sup>g</sup> Some vaccinations (e.g., DTaP, HiB, IPV, Pneumococcal Conjugate, and Rotavirus) have specific timing requirements; refer to the technical specification for further detail.

<sup>h</sup> No more than one gap in enrollment of up to 45 days during the last six months of the measurement year. In addition, the beneficiary must be enrolled in Medicaid or CHIP at the time of the survey.

---

<sup>i</sup> States that do not have 48 months of look-back data can still calculate the measure but should note this as a data limitation.

<sup>j</sup> No more than one gap in enrollment of up to 31 days during the measurement year.